1. Medtech Insight
  2. >>Archive

Caliper and Roche collaborate in lab-on-a-chip:

Caliper Technologies says a drug-development collaboration with Hoffmann-LaRoche will help it to develop diagnostic applications for its laboratory-on-a-chip technology. Roche has made an equity investment as part of an $8.5 million private financing deal. As a result of the deal, the two companies will adapt Caliper's assay technology for rapid drug screening.

Caliper Technologies says a drug-development collaboration with Hoffmann-LaRoche will help it to develop diagnostic applications for its laboratory-on-a-chip technology. Roche has made an equity investment as part of an $8.5 million private financing deal. As a result of the deal, the two companies will adapt Caliper's assay technology for rapid drug screening.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Veris Health Expands Oncology Monitoring Platform, Plans Implantable Sensor By 2026

 
• By Marion Webb

Banking on new billing codes for remote services, PAVmed’s Veris Health is expanding its oncology remote monitoring platform with Ohio State’s cancer center and developing an implantable physiological monitor to provide clinicians with continuous insights between treatment visits.

Ready For Lift-Off: India’s Medtech Industry Sees Rapid Advancement

 
• By Ashley Yeo

C-suite executives from Stryker, Intuitive Surgical and Fresenius passed a mainly upbeat verdict on the Indian medtech market and industry.

Medicare’s TCET Pathway Wins Acclaim From Early Users, Even As ‘Messy Middle’ Persists

 
• By Brian Bossetta

Some of the first manufacturers to receive Medicare coverage for their breakthrough devices through the Transitional Coverage for Emerging Technologies pathway praise CMS’ engagement and timelines in the process, despite some challenges around post-launch data collection.